Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.43 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.33 |
| ▸ | FNTA | P49354 | 2/20 | 0.31 |
| ▸ | FNTB | P49356 | 2/20 | 0.31 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9011395 | 0.88 | LPAR2 (0.37) | LPAR3LPAR2BTN3A1FNTAFNTB | |
| Ammonia Solution, Strong SCHEMBL10497024 | 0.86 | LPAR2 (0.36) | LPAR3LPAR2BTN3A1 | |
| SCHEMBL4393949 | 0.83 | LPAR3 (0.39) | LPAR3LPAR2BTN3A1LPAR1 | |
| SCHEMBL174096 | 0.83 | BTN3A1 (0.40) | LPAR3LPAR2BTN3A1FNTAFNTB | |
| SCHEMBL28985780 | 0.83 | CYP3A4 (0.47) | LPAR3LPAR2LPAR1 | |
| SCHEMBL474838 | 0.81 | LPAR3 (0.53) | LPAR3LPAR2LPAR1 | |
| Ammonia Solution, Strong SCHEMBL8023938 | 0.81 | BTN3A1 (0.39) | LPAR3LPAR2BTN3A1FNTAFNTB | |
| SCHEMBL10625461 | 0.81 | BTN3A1 (0.39) | LPAR3LPAR2BTN3A1FNTAFNTB | |
| SCHEMBL11677557 | 0.81 | BTN3A1 (0.39) | LPAR3LPAR2BTN3A1FNTAFNTB | |
| Ethylene SCHEMBL28068723 | 0.81 | BTN3A1 (0.39) | LPAR3LPAR2BTN3A1FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828972-B2 | Formulations containing alkylphosphocholines using novel negative charge carriers | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2014-09-09 | — | — | US | disclosed |
| US-20080090781-A1 | Formulations Containing Alkylphosphocholines Using Novel Negative Charge Carriers | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090781-A1 | Formulations Containing Alkylphosphocholines Using Novel Negative Charge Carriers | PHOSPHO1, SGMS2, LPCAT1 | LPAR3 54/4885LPAR2 55/4885BTN3A1 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.